Positive Readouts, High Bar: Why the Market Faded GPCR
Phase 3 is years away, GI side effects appeared at active amylin doses, and the oral GLP-1 bar is already high.
/ 5 items
#GPCR↓
Structure Therapeutics' Oral Obesity Pill Aleniglipron Hits Record 16.3% Weight Loss in Phase 2 Trial – Matches Injectables with No Plateau
Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Structure Therapeutics' Obesity Pill Shows Promising Weight Loss Results, Shares Surge
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.